ETXP.F Share Price Performance
US$0
0.00 (0.00%)
Price US$0
Share Pricen/a
e-therapeutics plc Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
ETXP.F Community Narratives
There are no narratives available yet.
There are no community narratives available.
Trending Discussion
Recently Updated Narratives
No recently updated narratives available.
Snowflake Analysis
e-therapeutics plc Key Details
Last Reported Earnings
Jan 31, 2024
Next Reporting Earnings
n/a
- -0.019
- 100.00%
- -3,511.32%
- 0%
About ETXP.F
- Founded
- 2001
- Employees
- 35
- CEO
- WebsiteView website
e-therapeutics plc engages in drug discovery research activities in the United Kingdom. The company offers HepNet, a hepatocyte-focused computational platform that enables identification of novel gene targets, improves drug design, and increases automation; and GalOmic, RNA interference (RNAi) platform that generates potent and safe GalNAc-siRNA therapeutics to selectively silence novel disease-associated genes in hepatocytes. Its preclinical products are ETX-312 to treat metabolic dysfunction-associated steatohepatitis; and ETX-407 for the treatment of dry age-related macular degeneration. The company also develops ETX-148 for haemophilia; ETX-291 to treat cardiometabolic disease, ETX-258 for heart failure; and ETX-394 to treat metabolic dysfunction-associated steatohepatitis. e-therapeutics plc incorporated in 2001 and is based in London, the United Kingdom.
